ELHT Evidence Hub
  • HOME
  • FOCUS ON YOUR SPECIALTY OR PROFESSION
  • STUDY SKILLS
  • FICTION, LEISURE AND SELF-HELP

Reasons for non-recruitment of eligible patients to a randomised controlled trial of secondary prevention after intracerebral haemorrhage: Observational study

21/4/2017

0 Comments

 
Author(s): Maxwell A.E.; Al-Shahi Salman R.; MacLeod M.J.; Joyson A.; Johnson S.; Ramadan H.; Bellfield R.; Byrne A.; McGhee C.; Rudd A.; Price F.; Vasileiadis E.; Holden M.; Hewitt J.; Carpenter M.; Needle A.; Valentine S.; Patel F.; Harrington F.; Mudd P.; Emsley H.; Gregary B.; Kane I.; Muir K.; Tiwari D.; Owusu-Agyei P.; Temple N.; Sekaran L.; Ragab S.; England T.; Hedstrom A.; Jones P.; Jones S.; Doherty M.; McCarron M.O.; Cohen D.L.; Tysoe S.

Source: Trials; Apr 2017; vol. 18 (no. 1)

Publication Date: Apr 2017

Publication Type(s): Article

Available in full text at Trials -  from BioMed Central

Abstract:Background: Recruitment to randomised prevention trials is challenging, not least for intracerebral haemorrhage (ICH) associated with antithrombotic drug use. We investigated reasons for not recruiting apparently eligible patients at hospital sites that keep screening logs in the ongoing REstart or STop Antithrombotics Randomised Trial (RESTART), which seeks to determine whether to start antiplatelet drugs after ICH. Method: By the end of May 2015, 158 participants had been recruited at 108 active sites in RESTART. The trial coordinating centre invited all sites that kept screening logs to submit screening log data, followed by one reminder. We checked the integrity of data, focused on the completeness of data about potentially eligible patients and categorised the reasons they were not randomised. Results: Of 108 active sites, 39 (36%) provided usable screening log data over a median of ten (interquartile range = 5-13) months of recruitment per site. During this time, sites screened 633 potentially eligible patients and randomised 53 (8%) of them. The main reasons why 580 patients were not randomised were: 43 (7%) patients started anticoagulation, 51 (9%) patients declined, 148 (26%) patients' stroke physicians were not uncertain about using antiplatelet drugs, 162 (28%) patients were too unwell and 176 (30%) patients were not randomised due to other reasons. Conclusion: RESTART recruited ~8% of eligible patients. If more physicians were uncertain about the therapeutic dilemma that RESTART is addressing, RESTART could have recruited up to four times as many participants. The trial coordinating centre continues to engage with physicians about their uncertainty. Trial registration: EU Clinical Trials, EudraCT 2012-003190-26. Registered on 3 July 2012.Copyright © 2017 The Author(s).

​Database: EMBASE
 
0 Comments



Leave a Reply.

    The following databases were searched:
    EMBASE,  MEDLINE, PsycINFO, BNI, CINAHL, 
    to find  ELHT staff publications

    Specialties

    All
    ANAESTHETICS
    CARDIOLOGY
    CRITICAL CARE
    DERMATOLOGY
    DIABETES
    ELDERLY CARE
    EMERGENCY CARE
    GASTROENTEROLOGY
    GYNAECOLOGY
    JUNIOR DOCTORS
    MAXILLOFACIAL
    NEONATOLOGY
    NEUROLOGY
    NURSING
    OBSTETRICS
    ONCOLOGY
    OPHTHALMOLOGY
    ORTHOPAEDICS
    PAEDIATRICS
    PATHOLOGY
    PHYSIOTHERAPY
    RADIOLOGY
    RENAL
    RESPIRATORY
    RHEUMATOLOGY
    STROKE
    SURGERY
    UROLOGY
    VASCULAR SURGERY

    RSS Feed

    Archives - past 2 years

    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017

Picture
Contact us
Picture
Support
Picture
Feedback
Picture
Performance
Picture
Catalogue
Picture
News
Picture
OpenAthens
Picture
Search
Picture
Privacy Policy
Connect with us
Picture
Picture
Picture